Medicare Star Excludes Diabetes Patients with Poor CVD Risk Factor Control

Overview

Journal Am J Manag Care

Specialty Health Services

Date 2015 Mar 6

PMID 25741874

Citations 15

Authors

Julie Schmittdiel

Marsha Raebel

Wendy Dyer

John Steiner

Glenn Goodrich

Andy Karter

Gregory Nichols

Affiliations

Soon will be listed here.

Abstract

Objectives: CMS recently added medication adherence to antihypertensives, antihyperlipidemics, and oral antihyperglycemics to its Medicare Star quality measures. These CMS metrics exclude patients with <2 medication fills (ie, "early nonadherence") and patients concurrently taking insulin. This study examined the proportion of patients with diabetes prescribed cardiovascular disease (CVD) medications excluded from Star adherence metrics and assessed the relationship of both Star-defined adherence and exclusion from Star metrics with CVD risk factor control.

Study Design: Cross-sectional, population-based analysis of 129,040 patients with diabetes aged ≥65 years in 2010 from 3 Kaiser Permanente regions.

Methods: We estimated adjusted risk ratios to assess the relationship between achieving Star adherence and being excluded from Star adherence metrics, with CVD risk factor control (glycated hemoglobin [A1C]<8.0%, low-density lipoprotein cholesterol [LDL-C]<100 mg/dL, and systolic blood pressure [SBP]<130 mm Hg) in patients with diabetes.

Results: Star metrics excluded 27% of patients with diabetes prescribed oral medications. Star-defined nonadherence was negatively associated with CVD risk factor control (risk ratio [RR], 0.95, 0.84, 0.96 for A1C, LDL-C, and SBP control, respectively; P<.001). Exclusion from Star metrics due to early nonadherence was also strongly associated with poor control (RR, 0.83, 0.56, 0.87 for A1C, LDL-C, and SBP control, respectively; P<.001). Exclusion for insulin use was negatively associated with A1C control (RR, 0.78; P<.0001).

Conclusions: Medicare Star adherence measures underestimate the prevalence of medication nonadherence in diabetes and exclude patients at high risk for poor CVD outcomes. Up to 3 million elderly patients with diabetes may be excluded from these measures nationally. Quality measures designed to encourage effective medication use should focus on all patients treated for CVD risk.

Citing Articles

Solving racial/ethnic disparities associated with Medicare Part D Star Ratings.

Dong X, Tsang C, Browning J, Sim Y, Wan J, Chisholm-Burns M Curr Med Res Opin. 2023; 39(7):963-971.

PMID: 37219396 PMC: 10423313. DOI: 10.1080/03007995.2023.2217654.

Effects of Part D Star Ratings on racial and ethnic disparities in health care costs.

Tsang C, Sim Y, Christensen M, Wang J Explor Res Clin Soc Pharm. 2023; 9:100250.

PMID: 37091627 PMC: 10113890. DOI: 10.1016/j.rcsop.2023.100250.

Racial and ethnic disparities due to Medicare Part D Star Ratings criteria among kidney transplant patients with diabetes, hypertension, and/or dyslipidemia.

Chisholm-Burns M, Spivey C, Tsang C, Wang J J Manag Care Spec Pharm. 2022; 28(6):688-699.

PMID: 35621720 PMC: 9499736. DOI: 10.18553/jmcp.2022.28.6.688.

Increasing Equity While Improving the Quality of Care: JACC Focus Seminar 9/9.

Schneider E, Chin M, Graham G, Lopez L, Obuobi S, Sequist T J Am Coll Cardiol. 2021; 78(25):2599-2611.

PMID: 34887146 PMC: 9172264. DOI: 10.1016/j.jacc.2021.06.057.

Racial and ethnic disparities associated with the measure for drug-drug interactions among Medicare beneficiaries.

Browning J, Tsang C, Wan J, Chisholm-Burns M, Dagogo-Jack S, Cushman W J Am Pharm Assoc (2003). 2021; 62(1):142-149.

PMID: 34509379 PMC: 8742744. DOI: 10.1016/j.japh.2021.08.023.

References

OConnor P, RUSH W, Pronk N, Cherney L . Identifying diabetes mellitus or heart disease among health maintenance organization members: sensitivity, specificity, predictive value, and cost of survey and database methods. Am J Manag Care. 1998; 4(3):335-42. View

Lau D, Nau D . Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004; 27(9):2149-53. DOI: 10.2337/diacare.27.9.2149. View

Sokol M, McGuigan K, Verbrugge R, Epstein R . Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005; 43(6):521-30. DOI: 10.1097/01.mlr.0000163641.86870.af. View

Johnson M, Singh H . Patterns of antihypertensive therapy among patients with diabetes. J Gen Intern Med. 2005; 20(9):842-6. PMC: 1490215. DOI: 10.1111/j.1525-1497.2005.0170.x. View

Donabedian A . Evaluating the quality of medical care. 1966. Milbank Q. 2005; 83(4):691-729. PMC: 2690293. DOI: 10.1111/j.1468-0009.2005.00397.x. View

Walker E, Molitch M, Kramer M, Kahn S, Ma Y, Edelstein S . Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care. 2006; 29(9):1997-2002. PMC: 1762037. DOI: 10.2337/dc06-0454. View

Derose S, Green K, Marrett E, Tunceli K, Cheetham T, Chiu V . Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Intern Med. 2013; 173(1):38-43. DOI: 10.1001/2013.jamainternmed.717. View

Reid R, Deb P, Howell B, Shrank W . Association between Medicare Advantage plan star ratings and enrollment. JAMA. 2013; 309(3):267-74. DOI: 10.1001/jama.2012.173925. View

Ho P, Rumsfeld J, Masoudi F, McClure D, Plomondon M, Steiner J . Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006; 166(17):1836-41. DOI: 10.1001/archinte.166.17.1836. View

10.

Adams A, Uratsu C, Dyer W, Magid D, OConnor P, Beck A . Health system factors and antihypertensive adherence in a racially and ethnically diverse cohort of new users. JAMA Intern Med. 2012; 173(1):54-61. PMC: 5105889. DOI: 10.1001/2013.jamainternmed.955. View

11.

Zgibor J, Orchard T, Saul M, Piatt G, Ruppert K, Stewart A . Developing and validating a diabetes database in a large health system. Diabetes Res Clin Pract. 2006; 75(3):313-9. DOI: 10.1016/j.diabres.2006.07.007. View

12.

Wienbergen H, Senges J, Gitt A . Should we prescribe statin and aspirin for every diabetic patient? Is it time for a polypill?. Diabetes Care. 2008; 31 Suppl 2:S222-5. DOI: 10.2337/dc08-s253. View

13.

Schmittdiel J, Uratsu C, Karter A, Heisler M, Subramanian U, Mangione C . Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med. 2008; 23(5):588-94. PMC: 2324158. DOI: 10.1007/s11606-008-0554-8. View

14.

Schmittdiel J, Uratsu C, Fireman B, Selby J . The effectiveness of diabetes care management in managed care. Am J Manag Care. 2009; 15(5):295-301. View

15.

Karter A, Parker M, Moffet H, Ahmed A, Schmittdiel J, Selby J . New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res. 2009; 44(5 Pt 1):1640-61. PMC: 2754552. DOI: 10.1111/j.1475-6773.2009.00989.x. View

16.

Yang Y, Thumula V, Pace P, Banahan 3rd B, Wilkin N, Lobb W . Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study. Clin Ther. 2009; 31(10):2178-88. DOI: 10.1016/j.clinthera.2009.10.002. View

17.

Rittenhouse D, Shortell S, Fisher E . Primary care and accountable care--two essential elements of delivery-system reform. N Engl J Med. 2009; 361(24):2301-3. DOI: 10.1056/NEJMp0909327. View

18.

Kenrik Duru O, Schmittdiel J, Dyer W, Parker M, Uratsu C, Chan J . Mail-order pharmacy use and adherence to diabetes-related medications. Am J Manag Care. 2010; 16(1):33-40. PMC: 3015238. View

19.

Rittenhouse D, Thom D, Schmittdiel J . Developing a policy-relevant research agenda for the patient-centered medical home: a focus on outcomes. J Gen Intern Med. 2010; 25(6):593-600. PMC: 2869424. DOI: 10.1007/s11606-010-1289-x. View

20.

Kind A, Bartels C, Mell M, Mullahy J, Smith M . For-profit hospital status and rehospitalizations at different hospitals: an analysis of Medicare data. Ann Intern Med. 2010; 153(11):718-27. PMC: 3058683. DOI: 10.7326/0003-4819-153-11-201012070-00005. View